Concerned About Dual Users? Then You May Want to Take NRT Products Off the Market

One of the major arguments that the major national health organizations make against the use of e-cigarettes for smoking cessation is that many smokers become "dual users" (i.e., people who use both e-cigarettes and real cigarettes). For example, the American Heart Association makes the following argument: "E-cigarette promoters claim the devices can help people quit smoking. But much more evidence is needed to determine if they are an effective way to quit. Research suggests that users are more likely to continue smoking along with vaping, which is referred to as “dual use." 

According to this argument, if a nicotine-containing smoking cessation product results in more smokers using both products than switching exclusively to the less harmful product, then that product is not "an effective way to quit."

The Rest of the Story

Recent data out of England reveal that 56.4% of smokers who use NRT products continue to smoke. In other words, 56.4% of NRT users in England are "dual users." By the American Heart Association's logic, it should be concluded that NRT is not "an effective way to quit" because smokers who try NRT are more likely to become dual users than to switch completely to NRT. However, we don't see the American Heart Association calling for bans or severe restrictions on NRT, not even flavored NRT.

The same report (called the Smoking Toolkit Study) revealed that in contrast to NRT, smokers who try e-cigarettes are more likely than not able to become sole users of e-cigarettes. In contrast to the 56% of smokers trying NRT who become dual users, only 36% of smokers who try e-cigarettes become dual users. By the American Heart Association's logic, they should conclude that e-cigarettes are an effective way to quit. However, we don't see the American Heart Association demanding that e-cigarettes remain on the market to help smokers quit.

So what explains the American Heart Association's stance on e-cigarettes vs. NRT as smoking cessation methods?

The first thing I always check when trying to explain logical discrepancies like this is money. An examination of funding received by the American Heart Association in 2020-2021 reveals that they received $40.7 million from pharmaceutical and biotech companies. Specifically, they received the following amount of money from individual companies within Big Pharma:

Alexion Pharmaceuticals: $1.3 million

Alnylam Pharmaceuticals: $0.75 million

Astra Zeneca: $6.3 million

Bayer Healthcare: $1.8 million

Boehringer Ingelheim Pharmaceuticals: $4.8 million (with a pledge of $4.8 million to be paid in future)

Janssen: $0.4 million

Jazz Pharmaceuticals: $0.25 million

Johnson & Johnson: $0.14 million

Kaneka Pharma America, LLC: $0.15 million

Merck: $0.15 million

Novartis: $1.7 million (with a pledge of $18.1 million to be paid in future years)

NovoNordisk: $1.6 million

Pfizer: $0.8 million

Sanofi: $1.7 million

This totals $21.8 million, with an additional pledge of $22.9 million, for a total of $44.7 million.

I'll be quite honest. If I or my company were receiving $44.7 million a year from Big Pharma, I, too, would not recommend that any of their products be taken off the market.